The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma.

[1]  P. Katsimbri.  The biology of normal bone remodelling , 2017, European journal of cancer care.

[2]  S. Avnet,et al.  Mesenchymal stroma: Role in osteosarcoma progression. , 2017, Cancer letters.

[3]  M. Donia,et al.  Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model , 2017, Nature Communications.

[4]  Jun Yan,et al.  γδ T Cells: Unexpected Regulators of Cancer Development and Progression. , 2017, Trends in cancer.

[5]  Mei Zhang,et al.  Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis , 2017, Oncotarget.

[6]  S. Dry,et al.  A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology , 2017, Oncotarget.

[7]  C. D. Savci-Heijink,et al.  Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent , 2017, Oncotarget.

[8]  S. Dry,et al.  Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model , 2017, Cell cycle.

[9]  M. Michalski,et al.  Macrophages and skeletal health , 2017, Pharmacology & therapeutics.

[10]  D. Heymann,et al.  Osteoprotegerin regulates cancer cell migration through SDF-1/CXCR4 axis and promotes tumour development by increasing neovascularization. , 2017, Cancer letters.

[11]  Qiaojun He,et al.  All-Trans Retinoic Acid Prevents Osteosarcoma Metastasis by Inhibiting M2 Polarization of Tumor-Associated Macrophages , 2017, Cancer Immunology Research.

[12]  T. Mcclanahan,et al.  Patterns of PD‐1, PD‐L1, and PD‐L2 expression in pediatric solid tumors , 2017, Pediatric blood & cancer.

[13]  R. Gillies,et al.  Cancer‐associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF‐κB activation , 2017, International journal of cancer.

[14]  Bohua Chen,et al.  Adipose-derived mesenchymal stem cells promote osteosarcoma proliferation and metastasis by activating the STAT3 pathway , 2017, Oncotarget.

[15]  Dazhi Yu,et al.  Tim3/Gal9 interactions between T cells and monocytes result in an immunosuppressive feedback loop that inhibits Th1 responses in osteosarcoma patients , 2017, International immunopharmacology.

[16]  F. Verrecchia,et al.  Analysis of gap junctional intercellular communications using a dielectrophoresis-based microchip. , 2017, European journal of cell biology.

[17]  N. McGranahan,et al.  Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.

[18]  D. Heymann,et al.  Cancer stem cells in osteosarcoma. , 2017, Cancer letters.

[19]  R. Cancedda,et al.  Mesenchymal Stem Cell‐Derived Extracellular Vesicles as Mediators of Anti‐Inflammatory Effects: Endorsement of Macrophage Polarization , 2017, Stem cells translational medicine.

[20]  T. Lagerweij,et al.  Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression , 2017, Clinical Cancer Research.

[21]  Dongxi Xiang,et al.  Prognostic value of inflammation-based scores in patients with osteosarcoma , 2016, Scientific Reports.

[22]  I. Endo,et al.  Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug , 2016, Oncotarget.

[23]  J. Rosocha,et al.  Activation, homing, and role of the mesenchymal stem cells in the inflammatory environment , 2016, Journal of inflammation research.

[24]  M. Schilham,et al.  Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy , 2016, Cancer Immunology, Immunotherapy.

[25]  S. Avnet,et al.  Tumor-Activated Mesenchymal Stromal Cells Promote Osteosarcoma Stemness and Migratory Potential via IL-6 Secretion , 2016, PloS one.

[26]  M. Heymann,et al.  Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma , 2016, Oncotarget.

[27]  Y. Mo,et al.  Mesenchymal Stem/Stromal Cells under Stress Increase Osteosarcoma Migration and Apoptosis Resistance via Extracellular Vesicle Mediated Communication , 2016, PloS one.

[28]  Dorian Obino,et al.  Inflammatory Osteoclasts Prime TNFα‐Producing CD4+ T Cells and Express CX3CR1 , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  M. Heymann,et al.  Drugs in early clinical development for the treatment of osteosarcoma , 2016, Expert opinion on investigational drugs.

[30]  M. Heymann,et al.  RANK–RANKL signalling in cancer , 2016, Bioscience reports.

[31]  B. Tang,et al.  In vitro generation of cytotoxic T lymphocyte response using dendritic cell immunotherapy in osteosarcoma. , 2016, Oncology letters.

[32]  U. Oppermann,et al.  Dendritic and mast cell involvement in the inflammatory response to primary malignant bone tumours , 2016, Clinical Sarcoma Research.

[33]  X. Zang,et al.  Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma , 2016, Scientific Reports.

[34]  N. Baldini,et al.  Multimodal transfer of MDR by exosomes in human osteosarcoma. , 2016, International journal of oncology.

[35]  C. Fan,et al.  Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3 , 2016, Oncotarget.

[36]  K. Ohashi,et al.  Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma , 2016, PloS one.

[37]  G. Freeman,et al.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. , 2016, Immunity.

[38]  Qing-lin Han,et al.  CD163(+) M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma. , 2016, International immunopharmacology.

[39]  P. Brousset,et al.  Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  S. Molyneux,et al.  RANKL blockade prevents and treats aggressive osteosarcomas , 2015, Science Translational Medicine.

[41]  Florian Engert,et al.  Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency , 2015, Nature Communications.

[42]  M. Donia,et al.  Tumor‐infiltrating lymphocytes for the treatment of metastatic cancer , 2015, Molecular oncology.

[43]  Yin Sj,et al.  Expression of B7-H3 in cancer tissue during osteosarcoma progression in nude mice. , 2015, Genetics and molecular research : GMR.

[44]  A. Patiño-García,et al.  Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner. , 2015, Cancer letters.

[45]  C. Jiang,et al.  Effectiveness evaluation of dendritic cell immunotherapy for osteosarcoma on survival rate and in vitro immune response. , 2015, Genetics and molecular research : GMR.

[46]  M. Miyazaki,et al.  Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma. , 2015, Oncology reports.

[47]  Ling-ling Sun,et al.  Trastuzumab enhanced the cytotoxicity of Vγ9Vδ2 T cells against zoledronate-sensitized osteosarcoma cells. , 2015, International immunopharmacology.

[48]  A. Dietz,et al.  Increased CTLA-4+ T cells and an increased ratio of monocytes with loss of class II (CD14+ HLA-DRlo/neg) found in aggressive pediatric sarcoma patients , 2015, Journal of Immunotherapy for Cancer.

[49]  Tao Liu,et al.  Pre-operative lymphocyte-to-monocyte ratio as a predictor of overall survival in patients suffering from osteosarcoma , 2015, FEBS open bio.

[50]  D. Heymann,et al.  Interleukin‐34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment , 2015, International Journal of Cancer.

[51]  L. Diller,et al.  A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma , 2015, Cancer Immunology, Immunotherapy.

[52]  R. Hoffman.  Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts , 2015, Nature Reviews Cancer.

[53]  E. Álava,et al.  Bone microenvironment signals in osteosarcoma development , 2015, Cellular and Molecular Life Sciences.

[54]  W. Weichert,et al.  Establishment of a patient-derived orthotopic osteosarcoma mouse model , 2015, Journal of Translational Medicine.

[55]  J. Blattman,et al.  Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions , 2015, Journal of immunotherapy.

[56]  A. L. Bosch,et al.  CD8+/FOXP3+-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study , 2015, Oncoimmunology.

[57]  Qiyu Zhang,et al.  Bone marrow mesenchymal stem cells promote osteosarcoma cell proliferation and invasion , 2015, World Journal of Surgical Oncology.

[58]  Yue Zhou,et al.  Expression of programmed death 1 is correlated with progression of osteosarcoma , 2015, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[59]  A. L. Bosch,et al.  Improved Survival in Osteosarcoma Patients with Atypical Low Vascularization , 2015, Annals of Surgical Oncology.

[60]  Y. Kimura,et al.  Antitumor and antimetastatic actions of dihydroxycoumarins (esculetin or fraxetin) through the inhibition of M2 macrophage differentiation in tumor-associated macrophages and/or G1 arrest in tumor cells. , 2015, European journal of pharmacology.

[61]  B. Fuchs,et al.  RANK Ligand Blockade with Denosumab in Combination with Sorafenib in Chemorefractory Osteosarcoma: A Possible Step Forward? , 2014, Oncology.

[62]  M. Ross,et al.  Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics , 2014, Genome Medicine.

[63]  Yongwon Choi,et al.  Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond , 2014, Front. Immunol..

[64]  David M. Thomas,et al.  Translational biology of osteosarcoma , 2014, Nature Reviews Cancer.

[65]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[66]  Carl R Walkley,et al.  Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? , 2014, Bone.

[67]  G. Nielsen,et al.  Programmed Cell Death Ligand 1 Expression in Osteosarcoma , 2014, Cancer Immunology Research.

[68]  M. Schilham,et al.  Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ , 2014, Journal of experimental & clinical cancer research : CR.

[69]  E. Kleinerman,et al.  Aerosol interleukin‐2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis , 2014, Pediatric blood & cancer.

[70]  S. Rosenberg,et al.  Exploiting the curative potential of adoptive T‐cell therapy for cancer , 2014, Immunological reviews.

[71]  G. Hannon,et al.  Patient-derived tumor xenografts: transforming clinical samples into mouse models. , 2013, Cancer research.

[72]  Yingze Zhang,et al.  B7-H3 is Overexpressed in Patients Suffering Osteosarcoma and Associated with Tumor Aggressiveness and Metastasis , 2013, PloS one.

[73]  C. Lewis,et al.  Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation. , 2013, Cancer research.

[74]  A. Evdokiou,et al.  The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis. , 2012, Biochimica et biophysica acta.

[75]  S. Fallarini,et al.  Invariant NKT cells increase drug‐induced osteosarcoma cell death , 2012, British journal of pharmacology.

[76]  Zhaoxu Li.  Potential of human γδ T cells for immunotherapy of osteosarcoma , 2012, Molecular Biology Reports.

[77]  Qiang Xu,et al.  Sensitization of human osteosarcoma cells to Vγ9Vδ2 T‐cell‐mediated cytotoxicity by zoledronate , 2012, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[78]  S. Chevalier,et al.  Induction of Osteogenesis in Mesenchymal Stem Cells by Activated Monocytes/Macrophages Depends on Oncostatin M Signaling , 2012, Stem cells.

[79]  H. Tsuchiya,et al.  Anti-TGF-β Antibody Combined with Dendritic Cells Produce Antitumor Effects in Osteosarcoma , 2012, Clinical orthopaedics and related research.

[80]  S. Gottschalk,et al.  Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma , 2011, Cancer Gene Therapy.

[81]  D. Scherman,et al.  Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[82]  D. Heymann,et al.  Bone sarcomas: pathogenesis and new therapeutic approaches , 2011 .

[83]  Qiang Xu,et al.  IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell-mediated killing through the Fas/Fas ligand pathway. , 2011, International immunopharmacology.

[84]  Anne-Marie Cleton-Jansen,et al.  Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents , 2011, Clinical Cancer Research.

[85]  P. Hogendoorn,et al.  Concise Review: Mesenchymal Tumors: When Stem Cells Go Mad , 2011, Stem cells.

[86]  L. Vermeulen,et al.  Cancer stem cell niche: the place to be. , 2011, Cancer research.

[87]  Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells , 2011, Cancer Immunology, Immunotherapy.

[88]  D. Heymann,et al.  Mifamurtide for the treatment of nonmetastatic osteosarcoma , 2011, Expert opinion on pharmacotherapy.

[89]  S. Dow,et al.  Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. , 2010, Journal of veterinary internal medicine.

[90]  M. Heymann,et al.  Safety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence , 2010, PloS one.

[91]  S. Gordon,et al.  Alternative activation of macrophages: mechanism and functions. , 2010, Immunity.

[92]  D. Heymann,et al.  Interleukin‐34 is expressed by giant cell tumours of bone and plays a key role in RANKL‐induced osteoclastogenesis , 2010, The Journal of pathology.

[93]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[94]  H. Heslop,et al.  Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[95]  D. Heymann,et al.  Mechanisms of bone repair and regeneration. , 2009, Trends in molecular medicine.

[96]  N. Athanasou,et al.  Canonical and non-canonical pathways of osteoclast formation. , 2009, Histology and histopathology.

[97]  B. Trinité,et al.  Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats. , 2008, Cancer research.

[98]  R. Zhao,et al.  Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. , 2008, Cell stem cell.

[99]  D. Heymann,et al.  Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases , 2008, Expert review of anticancer therapy.

[100]  E. Madon,et al.  Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells. , 2007, Cellular immunology.

[101]  J. Allison,et al.  The B7 Family and Cancer Therapy: Costimulation and Coinhibition , 2007, Clinical Cancer Research.

[102]  D. Heymann,et al.  RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases , 2007, Cellular and Molecular Life Sciences.

[103]  B. Le Goff,et al.  Human osteosarcoma cells express functional receptor activator of nuclear factor‐kappa B , 2007, The Journal of pathology.

[104]  H. Takayanagi.  Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems , 2007, Nature Reviews Immunology.

[105]  D. Heymann,et al.  Osteosarcoma: current status of immunotherapy and future trends (Review). , 2006, Oncology reports.

[106]  J. Pollard,et al.  Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.

[107]  S. Théoleyre,et al.  Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma , 2005, BMC Cancer.

[108]  S. Théoleyre,et al.  The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.

[109]  D. Heymann,et al.  Bisphosphonates: new therapeutic agents for the treatment of bone tumors. , 2004, Trends in molecular medicine.

[110]  D. Heymann,et al.  Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. , 2003, The American journal of pathology.

[111]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[112]  D. Heymann,et al.  Osteoclastic acidification pathways during bone resorption. , 2002, Bone.

[113]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[114]  R. Steinman,et al.  TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.

[115]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[116]  R. Hoffman.  Patient-Derived Mouse Models of Cancer , 2017, Molecular and Translational Medicine.

[117]  S. Kiany,et al.  Aerosol Delivery of Interleukin-2 in Combination with Adoptive Transfer of Natural Killer Cells for the Treatment of Lung Metastasis: Methodology and Effect. , 2016, Methods in molecular biology.

[118]  S. Gottschalk,et al.  Genetically modified T-cell therapy for osteosarcoma. , 2014, Advances in experimental medicine and biology.

[119]  Dean Anthony Lee,et al.  Natural killer cells for osteosarcoma. , 2014, Advances in experimental medicine and biology.

[120]  M. Padrines,et al.  Proteoglycans and osteolysis. , 2012, Methods in molecular biology.

[121]  S. Ferrari,et al.  Increased osteoclast activity is associated with aggressiveness of osteosarcoma. , 2008, International journal of oncology.

[122]  Y. Konttinen,et al.  Mast cells in atherosclerosis as a source of the cytokine RANKL , 2006, Clinical chemistry and laboratory medicine.

[123]  G. Parmiani,et al.  Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype , 2005, Cancer Immunology, Immunotherapy.

[124]  F. Levi-Schaffer,et al.  Osteoblast-like cell line maintains in vitro rat peritoneal mast cell viability and functional activity. , 1990, Immunology.